A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our investigational gene therapies are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects. Our investigational gene therapies use adeno-associated virus (AAV) vectors from our proprietary gene delivery platform, which we call our NAV® Technology Platform. AAV vectors are non-replicating viral delivery vehicles that are not known to cause disease. Our NAV Technology Platform has consisted of exclusive rights to a large portfolio of AAV vectors (NAV Vectors), including commonly used AAV8 and AAV9.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 170M | 170M | - | - | - | 470M |
| Net Income | -194M | -194M | -227M | -263M | -280M | 128M |
| EPS | $-3.76 | $-3.76 | $-4.59 | $-6.02 | $-6.50 | $2.91 |
| Free Cash Flow | -126M | -126M | -176M | -228M | -238M | 135M |
| ROIC | -89.8% | -107.0% | -87.5% | -84.5% | -54.3% | 36.8% |
| Gross Margin | - | - | - | - | - | 89.0% |
| Debt/Equity | 0.72 | 0.72 | 0.32 | 0.29 | 0.18 | 0.11 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -161M | -161M | -233M | -268M | -263M | 160M |
| Operating Margin | -94.6% | -94.6% | - | - | - | 34.0% |
| ROE | -188.7% | -107.0% | -87.5% | -84.5% | -54.3% | 16.7% |
| Shares Outstanding | 52M | 52M | 49M | 44M | 43M | 44M |
REGENXBIO Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 89.0%. At current prices, the estimated annualized return to fair value is +21.5%.
REGENXBIO Inc. (RGNX) has a 5-year average return on invested capital (ROIC) of -59.3%. This is below average and may indicate limited pricing power.
REGENXBIO Inc. (RGNX) has a market capitalization of $480M. It is classified as a small-cap stock.
REGENXBIO Inc. (RGNX) does not currently pay a regular dividend.
REGENXBIO Inc. (RGNX) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
REGENXBIO Inc. (RGNX) reported annual revenue of $170 million in its most recent fiscal year, based on SEC EDGAR filings.
REGENXBIO Inc. (RGNX) has a net profit margin of -113.8%. The company is currently unprofitable.
REGENXBIO Inc. (RGNX) generated $-126 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
REGENXBIO Inc. (RGNX) has a debt-to-equity ratio of 0.72. This indicates moderate leverage.
REGENXBIO Inc. (RGNX) reported earnings per share (EPS) of $-3.76 in its most recent fiscal year.
REGENXBIO Inc. (RGNX) has a return on equity (ROE) of -107.0%. A negative ROE may indicate losses or negative equity.
REGENXBIO Inc. (RGNX) has a 5-year average gross margin of 89.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 12 years of financial data for REGENXBIO Inc. (RGNX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
REGENXBIO Inc. (RGNX) has a book value per share of $1.99, based on its most recent annual SEC filing.